Aevi Genomic Medicine (GNMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2013 | 12-2012 | 12-2011 | |
| Cash Flows From Operating Activities | |||
| Net Income | -17,129 | -15,071 | -8,096 |
| Depreciation Amortization | 177 | 145 | 98 |
| Accounts receivable | 360 | 543 | 533 |
| Accounts payable and accrued liabilities | 185 | -26 | 764 |
| Other Working Capital | 571 | 829 | 1,208 |
| Other Operating Activity | 3,104 | 4,961 | -2,534 |
| Operating Cash Flow | $-12,732 | $-8,619 | $-8,027 |
| Cash Flows From Investing Activities | |||
| PPE Investments | -183 | -63 | -289 |
| Investing Cash Flow | $-183 | $-63 | $-289 |
| Cash Flows From Financing Activities | |||
| Common Stock Issued | 28,874 | 10,118 | 10,452 |
| Financing Cash Flow | $28,874 | $10,118 | $10,452 |
| Beginning Cash Position | 6,431 | 4,995 | 2,859 |
| End Cash Position | 22,390 | 6,431 | 4,995 |
| Net Cash Flow | $15,959 | $1,436 | $2,136 |
| Free Cash Flow | |||
| Operating Cash Flow | -12,732 | -8,619 | -8,027 |
| Capital Expenditure | -186 | -63 | -289 |
| Free Cash Flow | -12,918 | -8,682 | -8,316 |